Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4326
VanEck Video Gaming and eSports ETF
ESPO
$254M
| $175K | ﹤0.01% |
+1,685
| New | +$188K |
2025 Q4
0 quarters
|
|
|
GOCO
4327
DELISTED
GoHealth
GOCO
| $175K | ﹤0.01% |
81,181
+7,430
| +10% | +$25.4K |
2022 Q1
15 quarters
|
|
4328
Sagimet Biosciences
SGMT
$648M
| $174K | ﹤0.01% |
29,338
+22,929
| +358% | +$165K |
2025 Q3
1 quarter
|
|
4329
Journey Medical
DERM
$187M
| $174K | ﹤0.01% |
22,521
+4,955
| +28% | +$38.9K |
2025 Q2
2 quarters
|
|
4330
Transcontinental Realty Investors
TCI
$390M
| $174K | ﹤0.01% |
2,960
+282
| +11% | +$13.4K |
2022 Q2
14 quarters
|
|
4331
FT Vest US Equity Deep Buffer ETF July
DJUL
$485M
| $173K | ﹤0.01% |
3,644
-505
| -12% | -$23.8K |
2024 Q3
5 quarters
|
|
4332
LENSAR
LNSR
$82.9M
| $173K | ﹤0.01% |
14,857
+1,389
| +10% | +$15.9K |
2025 Q2
2 quarters
|
|
4333
TTEC Holdings
TTEC
$68M
| $170K | ﹤0.01% |
47,274
+389
| +0.8% | +$1.32K |
2013 Q2
50 quarters
|
|
4334
GSI Technology
GSIT
$216M
| $170K | ﹤0.01% |
+27,367
| New | +$195K |
2025 Q4
0 quarters
|
|
|
SII
4335
Sprott
SII
$2.99B
| $170K | ﹤0.01% |
1,734
+1,320
| +319% | +$117K |
2023 Q2
10 quarters
|
|
|
ARX
4336
Accelerant Holdings
ARX
$4.29B
| $170K | ﹤0.01% |
+10,375
| New | +$146K |
2025 Q4
0 quarters
|
|
4337
NI Holdings
NODK
$306M
| $170K | ﹤0.01% |
12,749
+1,359
| +12% | +$18.3K |
2017 Q2
34 quarters
|
|
|
AUGM
4338
FT Vest U.S. Equity Max Buffer ETF - August
AUGM
$64.8M
| $169K | ﹤0.01% |
+4,977
| New | +$168K |
2025 Q4
0 quarters
|
|
4339
Global X MLP & Energy Infrastructure ETF
MLPX
$3.47B
| $169K | ﹤0.01% |
+2,788
| New | +$167K |
2025 Q4
0 quarters
|
|
4340
PLAYSTUDIOS Inc
MYPS
$59.5M
| $168K | ﹤0.01% |
25,846
+1,335
| +5% | +$10.4K |
2022 Q2
14 quarters
|
|
|
ISBA
4341
Isabella Bank
ISBA
$291M
| $168K | ﹤0.01% |
+3,361
| New | +$142K |
2025 Q4
0 quarters
|
|
4342
FT Vest US Equity Max Buffer ETF March
MARM
$106M
| $168K | ﹤0.01% |
5,079
-723
| -12% | -$23.7K |
2024 Q3
5 quarters
|
|
|
DGOC
4343
FT Vest U.S. Equity Buffer & Digital Return ETF - October
DGOC
$4.95M
| $168K | ﹤0.01% |
+5,380
| New | +$166K |
2025 Q4
0 quarters
|
|
4344
CALL
Corcept Therapeutics
CORT
$12.6B
| $167K | ﹤0.01% |
4,800
-120,800
| -96% | -$9.49M |
2025 Q3
1 quarter
|
|
4345
Methanex
MEOH
$4.52B
| $167K | ﹤0.01% |
4,199
+2,249
| +115% | +$83.7K |
2013 Q2
50 quarters
|
|
4346
PUT
ChargePoint
CHPT
$249M
| $166K | ﹤0.01% |
25,000
| – | – |
2024 Q3
5 quarters
|
|
4347
One Stop Systems
OSS
$216M
| $166K | ﹤0.01% |
23,094
+19,588
| +559% | +$116K |
2025 Q3
1 quarter
|
|
|
KZIA
4348
Kazia Therapeutics
KZIA
$144M
| $165K | ﹤0.01% |
23,999
-1
| -0% | -$9 |
2024 Q4
4 quarters
|
|
4349
Barings BDC
BBDC
$904M
| $165K | ﹤0.01% |
+18,000
| New | +$159K |
2025 Q4
0 quarters
|
|
4350
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.7B
| $164K | ﹤0.01% |
1,145
| – | – |
2019 Q2
26 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.